Endocrine Abstracts

Introduction: Immune checkpoint blockade in cancer treatment causes frequent adverse events of auto-immune etiology. Ipilimumab (anti-CTLA-4 antibody) causes a hypophysitis in up to 10% of patients. In contrast, during treatment with nivolumab and pembrolizumab (both anti-PD-1 antibodies), hypophysitis is rare (<1%).Results: In the past year, we identified 4 cases of hypophysitis in patients treated with anti-PD-1 therapy (incidence 1% out of a total...